Lv1
20 积分 2025-05-27 加入
Apatinib mesylate in the treatment of advanced triple-negative breast cancer
20天前
已完结
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
1个月前
已完结
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
1个月前
已完结
A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer
1个月前
已完结
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
2个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2个月前
已完结
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
4个月前
已完结
Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles
4个月前
已关闭
Breast cancer in China
5个月前
已完结
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
5个月前
已完结
皖公网安备34019202002308
